Free Trial

IDEAYA Biosciences (IDYA) Competitors

IDEAYA Biosciences logo
$30.51 +1.25 (+4.27%)
Closing price 04:00 PM Eastern
Extended Trading
$30.42 -0.09 (-0.29%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDYA vs. RVMD, ABVX, RNA, CYTK, MRUS, RYTM, CRSP, GRFS, NUVL, and AXSM

Should you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Revolution Medicines (RVMD), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Merus (MRUS), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Grifols (GRFS), Nuvalent (NUVL), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

IDEAYA Biosciences vs. Its Competitors

Revolution Medicines (NASDAQ:RVMD) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Revolution Medicines presently has a consensus price target of $76.67, suggesting a potential upside of 41.95%. IDEAYA Biosciences has a consensus price target of $43.36, suggesting a potential upside of 42.11%. Given IDEAYA Biosciences' higher possible upside, analysts clearly believe IDEAYA Biosciences is more favorable than Revolution Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revolution Medicines
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93
IDEAYA Biosciences
1 Sell rating(s)
3 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.72

IDEAYA Biosciences has lower revenue, but higher earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$11.58M871.86-$600.09M-$4.50-12.00
IDEAYA Biosciences$7M381.99-$274.48M-$3.79-8.05

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by insiders. Comparatively, 2.5% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

IDEAYA Biosciences' return on equity of -31.42% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Revolution MedicinesN/A -41.78% -35.63%
IDEAYA Biosciences N/A -31.42%-29.45%

Revolution Medicines has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500.

In the previous week, Revolution Medicines had 7 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 15 mentions for Revolution Medicines and 8 mentions for IDEAYA Biosciences. Revolution Medicines' average media sentiment score of 0.78 beat IDEAYA Biosciences' score of 0.65 indicating that Revolution Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revolution Medicines
7 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEAYA Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Revolution Medicines and IDEAYA Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

Get IDEAYA Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IDYA vs. The Competition

MetricIDEAYA BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.67B$3.48B$6.17B$10.68B
Dividend YieldN/A2.27%5.70%4.84%
P/E Ratio-8.0523.3929.4727.36
Price / Sales381.99485.50589.24132.03
Price / CashN/A45.2825.8230.35
Price / Book2.4910.6112.526.69
Net Income-$274.48M-$52.56M$3.32B$276.59M
7 Day Performance13.97%4.94%2.43%0.97%
1 Month Performance18.53%16.10%8.78%3.95%
1 Year Performance-0.10%14.51%62.11%36.40%

IDEAYA Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IDYA
IDEAYA Biosciences
4.3936 of 5 stars
$30.51
+4.3%
$43.36
+42.1%
-4.2%$2.56B$7M0.0080News Coverage
RVMD
Revolution Medicines
4.4592 of 5 stars
$48.75
+1.1%
$74.64
+53.1%
+7.3%$9.02B$11.58M-10.83250Analyst Forecast
ABVX
Abivax
3.5934 of 5 stars
$95.63
+2.0%
$114.25
+19.5%
+787.4%$7.30BN/A0.0061Short Interest ↓
RNA
Avidity Biosciences
2.6117 of 5 stars
$48.96
-1.6%
$68.32
+39.5%
-5.1%$7.26B$10.90M-13.75190Insider Trade
CYTK
Cytokinetics
3.889 of 5 stars
$59.59
-0.7%
$76.64
+28.6%
+6.3%$7.18B$18.47M-11.68250
MRUS
Merus
1.4233 of 5 stars
$94.85
+0.5%
$93.12
-1.8%
+80.1%$7.14B$36.13M-17.2537Short Interest ↓
RYTM
Rhythm Pharmaceuticals
2.8957 of 5 stars
$100.77
0.0%
$106.64
+5.8%
+116.9%$6.70B$130.13M-33.48140Positive News
Analyst Forecast
Insider Trade
CRSP
CRISPR Therapeutics
1.9385 of 5 stars
$68.29
-6.5%
$71.71
+5.0%
+41.4%$6.65B$37.31M-12.58460Analyst Forecast
Insider Trade
Analyst Revision
Gap Up
GRFS
Grifols
3.9382 of 5 stars
$9.45
+1.4%
$10.30
+9.0%
+11.6%$6.41B$7.81B8.0823,822Positive News
NUVL
Nuvalent
2.5573 of 5 stars
$89.75
+1.9%
$118.89
+32.5%
-10.8%$6.35BN/A-18.3240Insider Trade
Analyst Revision
AXSM
Axsome Therapeutics
4.7758 of 5 stars
$121.15
-0.5%
$177.93
+46.9%
+37.1%$6.07B$385.69M-23.90380Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:IDYA) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners